Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

Subjects with locally advanced or metastatic solid tumours, including high-grade serious ovarian cancer, are being enrolled ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

As per Vantage Market Research, the Global Genomic Biomarkers Market has steadily grown due to the increasing demand for ...

At the same time, Imfinzi on its own has been approved in the EU for patients with mismatch repair deficient (dMMR) disease, the same indication that was cleared by the FDA in June. There was ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.

(HealthDay News) — After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering medications (GLMs) and among adults without diabetes ...

Tumour biomarkers is a term used to describe many different potential markers of cancer development and progression. These markers can come in many forms for example, proteins, biochemicals ...

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations. On April 14, 2025, the FDA approved a tablet ...